Savior Lifetec Corp. (4167) AI Stock Analysis

Savior Lifetec Corp.

(TPEx:4167)

Select Model

Rating:66Neutral

Price Target:TWD 20.00▲(3.90% Upside)

Action:initiatedcoverage

Date:11/10/26

Strong profitability, low leverage, and attractive valuation are the primary strengths. These are substantially offset by negative cash flow and weak technical momentum, resulting in an overall score of 66.

Positive Factors

Low Financial LeverageVery low leverage gives Savior Lifetec meaningful financial flexibility and reduces interest and refinancing pressure. The stronger equity base can help the company absorb earnings volatility, fund operations, and pursue development without relying heavily on additional borrowing.

Negative Factors

Negative 2025 Cash FlowThe reversal to negative operating and free cash flow creates a material quality-of-earnings concern because reported net income was high while cash generation weakened. If this persists, internal funding capacity could decline and the company may face greater execution or financing pressure.

Savior Lifetec Corp. (4167) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 6.32B
Dividend Yield: 4.18%
Average Volume (3M): 1.59M
Price to Earnings (P/E): 7.9
Beta (1Y): 0.47
Revenue Growth: -0.05%
EPS Growth: 64.82%
Country: TW
Employees: 375
Sector: General
Sector Strength: 55
Industry: Biotechnology

Savior Lifetec Corp. Business Overview & Revenue Model

Company Description

Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as pal...

Savior Lifetec Corp. Financial Statement Overview

Summary

Strong profitability and an exceptionally conservative balance sheet support the score, but sharply negative operating and free cash flow is a material weakness. The cash flow score was adjusted to the required minimum of 37 before averaging the three statement scores.

Income Statement

78Positive

Balance Sheet

92Very Positive

Cash Flow

28Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.12B	1.20B	1.22B	1.05B	1.27B	1.74B
Gross Profit	370.87M	423.41M	346.76M	220.95M	130.99M	307.87M
EBITDA	-71.06M	274.34M	314.02M	219.60M	260.73M	263.33M
Net Income	1.03B	533.64M	182.38M	30.03M	20.62M	-4.76M
Balance Sheet
Total Assets	5.16B	4.18B	4.38B	3.82B	4.41B	4.54B
Cash, Cash Equivalents and Short-Term Investments	2.72B	1.61B	2.12B	1.34B	1.65B	507.13M
Total Debt	290.91M	183.25M	177.78M	270.38M	803.27M	951.25M
Total Liabilities	768.96M	403.30M	860.02M	457.96M	1.04B	1.23B
Stockholders Equity	4.39B	3.78B	3.51B	3.35B	3.35B	3.31B
Cash Flow
Free Cash Flow	14.44M	-164.28M	399.92M	370.68M	547.60M	-263.94M
Operating Cash Flow	124.46M	-21.04M	518.38M	387.95M	581.77M	-168.34M
Investing Cash Flow	326.10M	-233.06M	-203.49M	181.19M	20.29M	18.53M
Financing Cash Flow	-38.35M	-280.56M	-39.74M	-572.22M	-7.48M	-41.37M

Savior Lifetec Corp. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4167 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4166	70Outperform	TWD 5.47B	22.78	―	―	―	―
TW:4167	66Neutral	TWD 6.30B	7.86	―	4.18%	-0.05%	64.82%
TW:1734	64Neutral	TWD 6.07B	17.33	―	3.13%	2.44%	-3.96%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4157	52Neutral	TWD 5.78B	37.38	―	―	530.40%	―
TW:4119	48Neutral	TWD 5.85B	95.69	―	1.55%	-18.83%	-87.54%

* General Sector Average

Performance Comparison

TW:4167 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4167	Savior Lifetec Corp.	19.25	2.57	15.39%
TW:1734	Sinphar Pharmaceutical Co. Ltd.	30.15	1.89	6.71%
TW:4119	SCI Pharmtech Corp.	48.50	-0.42	-0.85%
TW:4157	TaiGen Biopharmaceuticals Holdings Limited	8.29	-1.17	-12.37%
TW:4166	Orient Pharma Co., Ltd.	22.55	-1.95	-7.96%
TW:7754	Annji Pharmaceutical Co., Ltd.	69.40	24.90	55.97%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Savior Lifetec Corp. AI Stock Analysis